Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2014—DuraClone IM premixed dry reagent cocktails from Beckman Coulter Life Sciences standardize and streamline workflow for high-content flow cytometry in translational research studies involving identification of cellular subpopulations of the human immune system.
December 2014—Omicia, a genome interpretation company, announced the commercial availability of Opal Clinical, the company’s software-as-a-service solution for diagnostic testing organizations. With Opal Clinical, users can launch NGS tests faster and interpret results more accurately and quickly, the company said in a statement.
December 2014—Royal Philips announced it has acquired the CE mark for the diagnostic use of its Philips Digital Pathology Solution. European pathologists will now be able to use the full digital solution as an aid in diagnosis for routine pathology, including hematoxylin and eosin, immunohistochemistry, and special stained tissue sections.
December 2014—OvaGene Oncology announced it has entered into a research and development collaboration with Hitachi Chemical Research Center to bring novel mRNA-based signatures to the gynecologic oncology market. The collaboration is founded on Hitachi Chemical’s patented exosome technologies and OvaGene’s research, clinical validation, and translational focus.
December 2014—Aquaro Biosystems introduced its PaceSetter section mounting system, a benchtop instrument that automates the transfer of paraffin-embedded tissue sections directly from microtomes to glass slides.
December 2014—The PathScope 2 microscope imaging system from SPOT Imaging Solutions is designed to save pathologists up to two minutes per slide by streamlining routine slide examination. One click of the HistoSnap button captures the image during slide examination and imprints the image with the case number and reference mark, and then archives it to the laboratory information system, file server, or cloud storage.
December 2014—T2 Biosystems received FDA market authorization for its T2Candida Panel and T2Dx Instrument for the direct detection of candida species in human whole blood specimens from patients with symptoms of, or medical conditions predisposing patients to, invasive fungal infections.
December 2014—Sysmex America announced an amended distributorship agreement with Laboratory Supply Co. This agreement is for Sysmex reagents, controls, and instruments, including the Sysmex XS-1000i, Sysmex pocH-100i, Sysmex XP-300, XT-Series, and XN-Series automated hematology analyzers.
December 2014—Thermo Fisher Scientific announced the successful CE-IVD registration of its Ion PGM Dx System for sale in European countries. The system was developed using the Ion Torrent next-generation sequencing technology, currently used in clinical research laboratories to produce tests to uncover meaningful genetic information for a range of human conditions.
December 2014—Roche and ARK Diagnostics announced a distribution agreement that will enable laboratories to integrate ARK’s Methotrexate test into the Roche therapeutic drug monitoring menu for its Cobas c 501 and Cobas c 502 clinical chemistry analyzers.
